Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer - ecancer Dr Elena Elez speaks to ecancer about the health-related quality of life analyses from CheckMate 8HW. This clinical trial explores nivolumab plus ipilimumab

#ESMOGI25 | Dr. Elena Elez shares insights with @ecancer.org on the #CheckMate8HW trial 🔬

Watch the video here 👇

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC @myesmo.bsky.social #ESMOGI25 #crcsm #oncology
www.onclive.com/view/neoadju...

#ESMOGI25: #QualityofLife and #PainManagement data from the PANOVA-3 trial adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care for locally advanced #PancreaticAdenocarcinoma
Read more in the #ESMODailyReporter
🔗 buff.ly/RvF9pgo

Second-line treatment patterns after first-line immunotherapy in HCC - VJOncology Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses real-world data from the CHIEF cohort, which assessed second-line treatment...

🎥Julien Edeline, MD, PhD, shares CHIEF cohort data in HCC: 2L access drops post-IO 1L, but TKI outcomes stay consistent. IO rechallenge looks promising—though selection bias may play a role.

🔗 buff.ly/uhfMblQ

@myesmo.bsky.social #ESMOGI25 #CTSM

How we treat patients with advanced #BTC #CCA from #ESMOGI25. Expert centers, MDTs, molecular profiling, chemo-immunotherapy, and targeted agents @vjoncology.bsky.social

Advanced biliary cancer: expert care & molecular-guided treatment - VJOncology Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses advanced biliary tract cancer treatment, emphasizing the importance of expert center management...

🎥 @lorenzarimassa.bsky.social of HUNIMED discusses expert care & molecular testing in advanced biliary tract cancer. 1L chemo + IO (cis/gem + durva/pembro); 2L guided by biomarkers. From #ESMOGI25 Congress.

Watch: buff.ly/nZSaehg

@myesmo.bsky.social #Oncology #ImmunoOnc

Bowel cancer is rising in younger people, and screening is not the only answer At ESMO GI 2025 experts say rising cancer rates in younger adults may require not just better screening, but better awareness over the disease and its symptoms, and encouraging people to come forward.

Young people are increasingly being diagnosed with bowel cancer—often late.
At #ESMOGI25, experts urged a 3-pronged response:
🧪 Better tools
📣 More awareness
🩺 Earlier recognition
Full story: medicalnewsinsider.substack.com/p/bowel-canc...
#ColorectalCancer #CancerAwareness

TOP Immunotherapy trials from ESMO GI 2025 - OncoDaily Explore ESMO GI 2025 trials on immunotherapy in GI cancers: durvalumab + FLOT in gastric cancer, STRIDE in HCC, and BXCL701 combo in PDAC.

TOP Immunotherapy trials from ESMO GI 2025
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunotherapy #ESMOGI25 #ESMO #GIOnc

Olaparib Proves Active in Advanced Biliary Tract Cancer With HRR Mutations Olaparib demonstrated activity in patients who had advanced biliary tract cancer with HRR mutations.

In research presented at #ESMOGI25, olaparib showed activity in patients who had advanced biliary tract cancer with homologous recombination repair mutations. shorturl.at/dxPMg #gicsm

Studies Highlight Real-World Gaps in Third-Line mCRC and Evolving Role of Molecular Profiling in GI NETs Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Studies Highlight Real-World Gaps in Third-Line mCRC and Evolving Role of Molecular Profiling in GI NETs @myesmo.bsky.social #ESMOGI25 #oncology
www.onclive.com/view/studies...

The rise of early onset #ColorectalCancer calls for a new approach.

#EOCRC presents:

➡️ Distinct molecular traits
➡️ Emerging biomarkers (miR-195, miR-549a)
➡️ Strong case for earlier screening

It is time for tailored, biomarker-driven strategies.

#ESMOGI25

25 Posts Not To Miss From ESMO GI 2025 - OncoDaily The ESMO Gastrointestinal Cancers Congress (ESMO GI 2025) took place in Barcelona, Spain, from from July 2 to July 5, uniting global oncology professionals committed to improving outcomes across the s...

25 Posts Not To Miss From ESMO GI 2025
@myesmo.bsky.social
@lorenzarimassa.bsky.social
@arndtvogel.bsky.social
@ermanakkus.bsky.social
@rachnatshroff.bsky.social

oncodaily.com/societies/25...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOGI25 #ESMO #GIOnc

We had an amazing time in sunny #Barcelona for #ESMOGI25! 🇪🇸 ✨Thank you to all of you for stopping by and visiting us!
Catch up on all the research presented at ESMO GI here: hubs.li/Q03wlYf50
@myesmo.bsky.social #ESMOGI25 #ESMO #GIcancer #Spain

Gut Microbiome Linked to Treatment Response in Pancreatic Cancer The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

The composition of the gut microbiome appears to be associated with treatment response in pancreatic cancer, and adding immunotherapy to treatment may have a beneficial effect on the microbiome, according to research presented at #ESMOGI25. shorturl.at/T3y4N #gicsm #pancsm

#ESMOGI25: Study findings show that #ctDNA is a stronger #biomarker than carcinoembryonic antigen to select patients with #ColorectalCancer who may benefit from metastasis-directed therapy.

Read more in the #ESMODailyReporter

🔗 buff.ly/hqnXefN

#CRC

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC @myesmo.bsky.social #ESMOGI25 #oncology #crcsm www.onclive.com/view/efficac...

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma @ucl.ac.uk @myesmo.bsky.social #ESMOGI25 #oncology
www.onclive.com/view/ivoside...

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment #ESMOGI25 @myesmo.bsky.social #crcsm
www.onclive.com/view/real-wo...

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update - OncoDaily Botensilimab plus balstilimab delivers 21-month overall survival in MSS colorectal cancer, per updated Phase 1b data at ESMO GI 2025.

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Botensilimab #Balstilimab #MSSColorectalCancer #CRC #GIOnc #ESMOGI25

Adding Combo to TACE Improves Outcomes in HCC Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Adding atezolizumab and bevacizumab to on-demand treatment with TACE can improve outcomes in patients with previously untreated, unresectable #HCC who have an intermediate to high tumor burden, according to research presented at #ESMOGI25. shorturl.at/S8kWA #gicsm

Invikafusp Alfa Demonstrates Activity in Gastrointestinal Cancers Invikafusp alfa produced responses in patients with gastrointestinal cancers in a phase 1/2 trial.

Invikafusp alfa, a dual T-cell agonist targeting subsets of tumor-infiltrating lymphocytes, can elicit responses in patients with heavily pretreated gastrointestinal cancers, according to research presented at #ESMOGI25. shorturl.at/eWVlD #gicsm

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC #ESMOGI25 @myesmo.bsky.social
www.onclive.com/view/maic-an...

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma @myesmo.bsky.social #ESMOGI25 #oncology www.onclive.com/view/mfolfir...

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC @myESMO #ESMOGI25 #oncology www.onclive.com/view/rationa...

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC @myesmo.bsky.social #ESMOGI25 #oncology #crcsm www.onclive.com/view/triflur...

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC @myesmo.bsky.social #ESMOGI25 #oncology #crcsm www.onclive.com/view/ctdna-g...

Promising results of olaparib as a potential new #PrecisionOncology treatment for patients with biliary tract cancer #BTC #CCA and aberrant #HRR mutations. #ESMOGI25 #ESMOAmbassadors @myesmo.bsky.social

Prof Tabernero lecture on lessons learned from #GI translational research and the path forward at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Interesting mini-Oral presentation from Dr Francesca Negri about the assessment of tumour immune microenvironment as a prognostic marker in Locally Advanced Rectal Cancer using a cohort from STAR-01 #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors